

30 January 2020 EMA/135953/2020 Human Medicines Evaluation Division

Statement indicating compliance with the agreed completed paediatric investigation plan

Medicinal product	
MabThera	
rituximab	
Pharmaceutical form(s):	See Annex A of the CHMP Opinion
Strength(s):	See Annex A
Route(s) of administration:	See Annex A
Packaging and package	See Annex A
size(s):	
Number(s)in the Community	See Annex A
Register of Medicinal Products:	

Marketing Authorisation Holder (MAH):	
Name and address of the MAH:	Roche Registration GmbH Emil-Barell-Strasse 1 79639 Grenzach-Wyhlen GERMANY

Procedure	
Procedure number:	EMEA/H/C/000165/II/0168

Further to the compliance check performed under Article 23 of Regulation (EC) No 1901/2006, and in accordance with Article 28(3) and Article 45(3) of the said Regulation it is concluded that:

- the development of this product has complied with all measures in the agreed paediatric investigation plan P/0064/2019. All studies in the agreed paediatric investigation plan P/0064/2019 were conducted after the entry into force of that Regulation,

- the Summary of Product Characteristics reflects the results of studies conducted in compliance with this agreed paediatric investigation plan.

In accordance with Article 23a of Regulation (EC) No 1234/2008, this statement indicating compliance with the agreed completed paediatric investigation plan P/0064/2019 is included in the technical dossier.

Official addressDomenico Scarlattilaan 6 • 1083 HS Amsterdam • The NetherlandsAddress for visits and deliveriesRefer to www.ema.europa.eu/how-to-find-usSend us a questionGo to www.ema.europa.eu/contactTelephone +31 (0)88 781 6000An agency of the European Union



© European Medicines Agency, 2020. Reproduction is authorised provided the source is acknowledged.